Goldman Sachs Group Inc. Makes New Investment in BioXcel Therapeutics, Inc. $BTAI

Goldman Sachs Group Inc. acquired a new position in shares of BioXcel Therapeutics, Inc. (NASDAQ:BTAI) in the first quarter, according to the company in its most recent 13F filing with the SEC. The institutional investor acquired 24,794 shares of the company’s stock, valued at approximately $50,000. Goldman Sachs Group Inc. owned about 0.41% of BioXcel Therapeutics as of its most recent filing with the SEC.

Other large investors also recently bought and sold shares of the company. Murchinson Ltd. purchased a new position in BioXcel Therapeutics during the first quarter worth about $276,000. Northern Trust Corp raised its holdings in BioXcel Therapeutics by 81.4% during the fourth quarter. Northern Trust Corp now owns 73,910 shares of the company’s stock worth $28,000 after purchasing an additional 33,161 shares in the last quarter. Finally, Squarepoint Ops LLC raised its stake in shares of BioXcel Therapeutics by 203.9% during the 4th quarter. Squarepoint Ops LLC now owns 72,046 shares of the company’s stock worth $27,000 after buying an additional 48,336 shares in the last quarter. Hedge funds and other institutional investors own 30.68% of the company’s stock.

Analyst Ratings Changes

BTAI has been the subject of a number of analyst reports. Wall Street Zen downgraded BioXcel Therapeutics from a “hold” rating to a “sell” rating in a research note on Friday, June 27th. Zacks Research cut BioXcel Therapeutics from a “strong-buy” rating to a “hold” rating in a research report on Tuesday, August 26th. Finally, HC Wainwright reiterated a “buy” rating and issued a $10.00 price objective on shares of BioXcel Therapeutics in a research report on Monday, September 15th. One analyst has rated the stock with a Strong Buy rating, three have issued a Buy rating, one has given a Hold rating and one has assigned a Sell rating to the company. Based on data from MarketBeat.com, the company currently has a consensus rating of “Moderate Buy” and a consensus target price of $39.75.

BioXcel Therapeutics Trading Down 2.3%

BioXcel Therapeutics stock opened at $2.56 on Wednesday. The stock has a market cap of $40.99 million, a PE ratio of -0.20 and a beta of 0.20. The stock has a 50-day moving average price of $3.53 and a 200 day moving average price of $2.38. BioXcel Therapeutics, Inc. has a 52 week low of $1.17 and a 52 week high of $13.28.

BioXcel Therapeutics (NASDAQ:BTAI) last issued its quarterly earnings results on Tuesday, August 12th. The company reported ($2.45) EPS for the quarter, missing analysts’ consensus estimates of ($2.30) by ($0.15). The firm had revenue of $0.12 million for the quarter, compared to analyst estimates of $0.21 million. On average, equities analysts predict that BioXcel Therapeutics, Inc. will post -24.39 EPS for the current year.

About BioXcel Therapeutics

BioXcel Therapeutics, Inc, a commercial-stage biopharmaceutical company, engages in utilizing artificial intelligence approaches to develop transformative medicines in neuroscience and immuno-oncology. The company's drug re-innovation approach leverages existing approved drugs and/or clinically validated product candidates together with big data and proprietary machine learning algorithms to identify new therapeutic indices.